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Abstract
Background: Dinitrochlorobenzene-induced contact hypersensitivity is widely considered as a cell-mediated rather than
antibody-mediated immune response. At present, very little is known about the role of antigen-specific antibodies and B
cells in the development of dinitrochlorobenzene-induced hypersensitivity reactions, and this is the subject of the present
investigation.
Methodology/Principal Findings: Data obtained from multiple lines of experiments unequivocally showed that the
formation of dinitrochlorobenzene-specific Abs played an important role in the development of dinitrochlorobenzene-
induced contact hypersensitivity. The appearance of dinitrochlorobenzene-induced skin dermatitis matched in timing the
appearance of the circulating dinitrochlorobenzene-specific antibodies. Adoptive transfer of sera containing dinitrochlor-
obenzene-specific antibodies from dinitrochlorobenzene-treated mice elicited a much stronger hypersensitivity reaction
than the adoptive transfer of lymphocytes from the same donors. Moreover, dinitrochlorobenzene-induced contact
hypersensitivity was strongly suppressed in B cell-deficient mice with no DNCB-specific antibodies. It was also observed that
treatment of animals with dinitrochlorobenzene polarized Th cells into Th2 differentiation by increasing the production of
Th2 cytokines while decreasing the production of Th1 cytokines.
Conclusions/Significance: In striking contrast to the long-held belief that dinitrochlorobenzene-induced contact
hypersensitivity is a cell-mediated immune response, the results of our present study demonstrated that the production
of dinitrochlorobenzene-specific antibodies by activated B cells played an indispensible role in the pathogenesis of
dinitrochlorobenzene-induced CHS. These findings may provide new possibilities in the treatment of human contact
hypersensitivity conditions.
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Introduction
Dinitrochlorobenzene (DNCB)-induced contact hypersensitivity
(CHS) of the skin in mice is a commonly-used animal model for
studying the pathogenesis of contact dermatitis [1]. Mechanistically,
it is generally thought that upontopical application, DNCB or other
chemicals with a similar structure, such as 2,4-dinitrofluorobenzene
and picryl chloride, can complex with various skin proteins to form
covalent conjugates and thereby function as immunogen(s). DNCB-
modified macromolecules are then internalized by local APCs, such
as skin Langerhans cells, dermal dendritic cells and macrophages,
processed and presented to T cells for activation [2,3]. Approx-
imately twenty-four hours after subsequent exposures to DNCB
(often referred to as ‘‘challenges’’), macrophages were found to
accumulate at the site of DNCB exposure [4], contributing to the
developmentof dermatitis (e.g., ear swelling and skin inflammation).
At present, the prevailing explanation is that the pathogenesis of
DNCB-induced CHS is predominantly the result of T cell-mediated
immune responses [4–7]. However, there were also studies in recent
years suggesting the possible involvement of B cells in the
development of CHS. It was recently reported that animals exposed
to low molecular weight chemical allergens, such as 2,4-dinitro-
fluorobenzene, picryl chloride and oxazolone, had an increased B
cell population in their draining lymph nodes [8]. Similarly,
exposure of animals to contact allergens also led to an increased
percentage of antigen-specific B-1 cells (which mostly produce IgM)
inthedraininglymphnodes[9–11].Besidesthesescatteredpiecesof
data, however, little is known about the roles of Abs and B cells in
the development of DNCB-induced hypersensitivity reactions.
In the present study, we have sought to explore the pathogenic
role of DNCB-specific Abs in the development of CHS in a mouse
model. We have gathered several lines of experimental evidence
showing that the formation of DNCB-specific Abs plays an
important role in the development of DNCB-induced CHS.
Results
Induction of Skin CHS in Mice by DNCB
Induction of ear swelling by topical application of DNCB (or
other similar chemicals) in mice has been widely used for decades
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7703as an animal model for studying the pathogenesis of CHS.
Typically, the animals are first sensitized once by painting the
chemical on their shaved back or abdominal skin. Five days later,
they are challenged on one of the ears. The thickness of the ear is
measured 24 h later to determine the level of swelling [12,13]. In
the present study, we have modified the DNCB treatment scheme
by giving multiple sensitizations with adequate time intervals. We
found that different schemes of DNCB administration produced
variable degrees of ear swelling (data are summarized in Table
S1). In general, factors including gender, DNCB dosage (i.e., the
concentration of its solution and the volume applied), solvent and
method of administration, did not appear to significantly affect the
severity of DNCB-induced ear swelling. However, the number of
DNCB sensitizations and particularly the duration between the
sensitizations were found to be the most important factors affecting
the severity of ear swelling. If the interval between the first and
second DNCB sensitizations was sufficiently long (7 days and up),
strong ear swelling was readily observed. Otherwise, the severity of
DNCB-induced ear swelling in the animals would be low (,50%)
and very inconsistent (Table S1).
Using an optimized DNCB sensitization scheme (Figure 1A),
we then characterized the pathogenic changes in the back and ear
skins. We found that all animals developed strong skin hypersen-
sitivity reactions in the painted back skin after $8 days of initial
DNCB sensitization (Figure 1B). The scaring was severe and
lasted for a couple of days. Similarly, at 24 h after DNCB
challenge of the ear (note that the ear had no prior exposure to
DNCB), significant ear swelling was also readily observed in
animals previously exposed to DNCB compared to control
animals (Figure 1C). The ear swelling following DNCB challenge
was not due to a non-specific inflammatory response to the
chemical (Figure S1).
Histopathological analysis showed that pathological changes of
both back and ear skins were mainly located within the dermis and
characterized by the presence of inflammatory infiltration,
vascular congestion, and moderate edema (representative slides
of ear skin tissue are shown in Figure 1D). Administration of
dexamethasone (DEX) (at 10 mg/kg b.w., i.m.) once every two
days during DNCB treatment markedly reduced back skin
inflammation (Figure 1B) and also ear swelling (Figure 1C, 1D).
Immunohistochemical analysis showed that DNCB-painted mice
had more IL-5-positive cells but fewer IFN-c-positive cells in their
back skin compared to vehicle-treated animals (Figure 1E).
Similarly, more IL-5-positive cells but less IFN-c-positive cells were
observed in the ear tissue one day after DNCB challenge compared
to vehicle-treatedanimals (Figure1E). Administration of DEX was
accompanied by a marked decrease in IL-5-positive cells in the ear
tissue (data not shown). Collectively, these results suggest a
predominance of Th2 cytokine-mediated inflammatory response
at the sites of DNCB exposure.
In these experiments, the body and organ weight changes were
also determined (summarized in Figure S2). Weight index for
each organ was calculated according to the following formula:
weight index=organ wet weight (mg)/body weight (g). We found
that treatment with DNCB did not markedly alter the body weight
or spleen weight index, but did decrease the thymus weight index
by ,30% compared to vehicle-treated animals. Treatment with
DNCB plus DEX decreased the animal body weight by 11%,
spleen weight index by 60%, and thymus weight index by 80%
compared to DNCB treatment alone.
Role of DNCB-Specific Abs in the Induction of CHS
To probe the role of DNCB-specific Abs in the induction of
CHS, we determined whether the onset of CHS coincided with
the appearance of DNCB-specific Abs, and also whether the
severity of CHS correlated with serum levels of DNCB-specific
Abs.
We found that treatment of animals with DNCB (Figure 2A)
increased serum levels of DNCB-specific Abs, and this effect
largely depended on the duration and frequency of DNCB
treatments. No appreciable levels of DNCB-specific Abs were
found in sera of DNCB-treated mice until at least 8 days after the
first DNCB sensitization (Figure 2B, 2C). Various subtypes of
DNCB-specific Abs, including IgG, IgG1, IgG2a, IgG2b and IgA
(but not IgE), were detected in the serum of these animals at $8
days following the initial DNCB sensitization(s) (Figure 2D and
Figure S3). In addition, triple sensitizations with DNCB
induced higher titers of DNCB-specific Abs compared to double
sensitizations (a representative data set is shown in Figure 2E).
Treatment of these animals with DEX decreased by over 50%
the serum levels of DNCB-specific Abs, including IgA, IgG, and
its subtypes, IgG1, IgG2a and IgG2b (Figure 2D and Figure
S3). For comparison, we have also determined the total serum Ab
levels (summarized in Figure S4). DNCB treatment did not
change the serum levels of total IgM, IgG2a, IgG2b and IgG3,
but it slightly increased the serum levels of total IgA, IgG and
IgG1. The effect of DEX on the total serum Ab levels was very
mild.
By comparing the appearance of DNCB-specific Abs with the
occurrence of skin inflammation, we found that before DNCB-
specific Abs became detectable in serum, no appreciable signs of
skin reactions at the site of DNCB sensitization could be observed.
Once the skin inflammation started to appear in the DNCB-
treated animals (Figure 1B), large quantities of DNCB-specific
Abs were always concomitantly detected in their sera (represen-
tative data for IgG are shown in Figure 2B, 2C). In general, a
higher degree of severity was accompanied by the presence of
higher levels of DNCB-specific Abs in serum. For instance, triple
sensitizations with DNCB induced stronger back skin inflamma-
tion compared to double or single sensitization(s), which agreed
with the change in the levels of DNCB-specific serum Abs
(Figure 2E). Similarly, treatment with DEX reduced the back
skin inflammation, to an extent that was comparable to its
reduction of the serum levels of DNCB-specific Abs (Figure 2D
and Figure S3).
Similarly, the severity of ear swelling following DNCB
challenge also closely matched the serum levels of DNCB-
specific Abs. We observed that when the animals had no
detectable serum levels of DNCB-specific Abs, their ear swelling
w a sa l w a y sm i l d ,a n dt h ep a r a m e t e ro fD ear thickness (i.e.,
thickness of the DNCB-challenged ear/the control ear - 1), was
almost always below 0.5, and severe ear swelling was always
observed along with high titers of serum DNCB-specific Abs,
particularly in the cases of triple sensitizations (Table S1,
compare Exp-1 through Exp-9 with Exp-10 and Exp-11). As
shown in Figure 2F (data from a representative experiment), the
ear thickness in mice topically sensitized twice with DNCB was
increased by 82% at 24 h after DNCB challenge compared to
control animals, whereas the ear thickness in mice with triple
sensitizations was increased by 113%.
Induction of CHS by Adoptive Transfer of DNCB Antisera
To provide definitive evidence that DNCB-specific Abs played
an essential role in the development of skin hypersensitivity
reactions, we conducted experiments by transferring sera collected
from DNCB-sensitized mice to determine whether the presence of
DNCB-specific Abs alone could transfer similar hypersensitivity
skin reactions to recipient animals (with no prior exposure to
Role of Antibodies in CHS
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animals were treated multiple times with DNCB to induce strong
CHS, and their sera were tested to ascertain that high titers of
DNCB-specific Abs were produced before they were used for
adoptive transfer into recipient animals. Meanwhile, sera from
mice that were not exposed to DNCB were used as control
(Figure 3A). In addition, for the purpose of comparison,
lymphocytes from lymph nodes were also prepared from the
same animals (DNCB-treated and control animals) and used for
adoptive transfer.
Eighteen and 66 h after the adoptive transfer of sera
containing high titers of DNCB-specific Abs into the mice,
Figure 1. Induction of CHS by topical administration of DNCB and its suppression by DEX. A. The DNCB treatment schedule used in this
experiment. As shown, the mice were first painted with 100 mL of 2% DNCB or vehicle at their shaved back on D0 as the first sensitization. On D12,
mice received the second sensitization with DNCB in the same way as the first one. On D17, mice were challenged with 20 mL of 2% DNCB or ETOH
(the vehicle) painted on their left ears twice with a 60-min interval. Twenty-four h later (on D18), the ear swelling was evaluated by measuring the
thickness and weight. Other assays were also performed after the animals were sacrificed. DEX was administrated through i.m. injection at 10 mg/kg
b.w. every other day starting from a day before the first sensitization until the end of the experiment. B. The severity of back skin inflammation after
sensitization with DNCB. The photos were taken at 8 days after sensitization with DNCB. C. The ear swelling indices (ear thickness and ear weight).
They were calculated according to the differences between the DNCB-challenged left ears and the unchallenged right ears using the following
formula: index=the measured value for the left ear/the measured value for the right ear - 1. * P,0.01 compared to animals treated with DNCB alone.
Each value is the mean6S.D. (N=6). D. Histological changes in the ears (H/E staining). E. Comparison of IFNc and IL-5 immunohistochemical staining
in the back and ear skins of mice treated with DNCB or vehicle. The back skin and the left ear tissues were harvested on D18 (one day following DNCB
challenge of the ear). The skin sections were stained with anti-mouse IFNc or anti-mouse IL-5, respectively. Six animals per group were used, and a
representative slide for each group is shown.
doi:10.1371/journal.pone.0007703.g001
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PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7703Figure 2. Role of DNCB-specific Abs in the induction of CHS. A. The DNCB treatment schedule used in this experiment. On D0, mice were
sensitized by painting DNCB or vehicle on their shaved backs, respectively. On D7 and D13, mice were painted with DNCB or vehicle on their shaved
back again in the same way as the first sensitization. On D17, mice were challenged with painting DNCB or vehicle, respectively, on their left ears.
Mice received a total of three back paintings and one ear challenge, and the experiment was terminated on D18. B and C. Serum levels of DNCB-
specific IgG Abs on different days following DNCB treatment. The blood samples were collected on the following days: D7 (right before the second
sensitization), D11 (between the second and third sensitizations), D14 (after the third sensitization), D17 (right before DNCB ear challenge), and D18
(the animals were sacrificed at 24 h after DNCB challenge). Each value is the mean6S.D. (N=4). D. Comparison of DNCB-specific IgA, IgG, IgG1, IgG2a,
and IgG2b Ab levels in different treatment groups. Each value is the mean6S.D. (N=6). E. Serum DNCB-specific IgG Abs on D18. The double DNCB
sensitizations before challenge were applied on D0 and D12 as described in Figure 1A, whereas the triple sensitizations were applied on D0, D7 and
D13 as depicted in Figure 2A. Both groups were received DNCB challenge on D17 and terminated a day later. One representative curve from each
group (N=4) is shown. F. Ear swelling as measured according to the thickness of left/right ear - 1. * P,0.01 compared to the DNCB treatment group.
Each value is the mean6S.D. (N=4).
doi:10.1371/journal.pone.0007703.g002
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swelling compared to animals that received the DNCB-negative
sera (Figure 3B). The recipient animals that received DNCB
antisera produced a sustained ear swelling after DNCB challenge
on their left ears even at 66 h after the transfer. Also, in these
animals, the presence of DNCB-specific Abs in their sera was
readily detected (Figure 3C). Notably, the ear swelling in
animals receiving the DNCB-positive lymphocytes was not
significantly different from animals that received the DNCB-
negative sera or lymphocytes or sera plus lymphocytes. The
recipients that were adoptively transferred with DNCB-positive
sera plus DNCB-positive lymphocytes produced a reduced level
of ear swelling after DNCB challenge compared to animals
receiving theDNCB-positivesera alone (tested at upto 66 h post-
transfer) (Figure 3B). Overall, the DNCB-specific IgG levels in
the sera of recipients were closely associated with the severity of
Figure 3. Effect of adoptive transfer of sera and/or lymphocytes on the development of DNCB-induced CHS. A. DNCB-specific IgG Abs
in the sera of donor mice. The DNCB-positive donors (close circleN) were exposed to DNCB three or four times with sufficient time intervals and the
DNCB-negative donors (open circle #) were only treated with vehicle. B. Ear swelling of recipient mice from different treatment groups. After i.v.
injection of serum only, LN lymphocytes (LNC) only, or combination of serum + LNC from either DNCB-positive donors (Pos) or DNCB-negative donors
(Neg), the recipient animals in these 6 different treatment groups were challenged on their left ears with DNCB and then their ear swelling was
measured 18 h (left panel) and 66 h (right panel) later. C. DNCB-specific IgG Abs in the sera of recipient animals from the 6 treatment groups. The
levels were determined at 66 h after DNCB ear challenge. * P,0.01 compared to the positive LNC group (mice adoptively transferred with DNCB-
positive lymphocytes). Each value is the mean6S.D. (N=5 for each of the three Pos groups, and N=3 for each of the three Neg groups).
doi:10.1371/journal.pone.0007703.g003
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following rank order (from high to low): recipients of the DNCB-
positive sera only . recipients of the DNCB-positive sera plus
lymphocytes & recipients of DNCB-positive lymphocytes only <
recipients of DNCB-negative sera only < recipients of DNCB-
negative lymphocytes < recipients of DNCB-negative sera plus
lymphocytes (Figure 3C).
Role of B Cells in DNCB-Induced CHS
To provide additional support for the suggested role of DNCB-
specific Abs in the development of CHS, we also conducted studies
using B cell-deficient (B-KO) mice. The B-KO mice and their
background control (i.e., the WT C57BL/6J mice) were treated
with DNCB or vehicle as described in Figure 4A, and their ear
swelling was measured at 24 h after DNCB challenge. While the
Figure 4. Comparison of the severity of CHS in B cell-deficient mice and control WT mice. A. The DNCB treatment schedule used in this
experiment. The mice were sensitized on their shaved back on D0. On D7 and D14, mice were received the second and third sensitization with DNCB on
their shaved back the same as the first sensitization. They were challenged on their left ears on D21, and sacrificed on D22. B. Ear swelling index in B-KO
mice and WT mice. The animals were separated into 4 groups: WT-DNCB, WT-control, B-KO-DNCB, B-KO-control. C and D. Time-dependent changes of
serum DNCB-specific IgG Abs in B-KO mice and WT mice. Serum Abs were determined on D7, D14, D18, D22 and D29 (note that one of the mice was
sacrificed on D29 whereas all other mice were sacrificed on D22). E. Comparison of the back skin dermatitis between B-KO mice and WT mice. The
photos show the degree of inflammatory responses in the shaved back skin of animals following second sensitization with DNCB or vehicle. * P,0.01
compared to WT-DNCB mice. Each value is the mean6S.D. (N=3 for the vehicle treatment groups and N=6 for the DNCB treatment groups).
doi:10.1371/journal.pone.0007703.g004
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showed a significantly lower level of ear swelling (26% increase, see
Figure 4B). Notably, we also observed that the DNCB-specific
serum IgG levels in the B-KO mice remained at the baseline levels
following multiple DNCB treatments (Figure 4C), which
demonstrated that the B-KO mice could not produce antigen-
specific Abs. However, the WT mice had an increased
DNCB-specific serum IgG level after the second sensitization,
which occurred after D7 and reached plateau around D22
(Figure 4C, 4D). Also, after the second sensitization with DNCB
on their shaved back skin, there was a more pronounced skin
dermatitis appearing on the backs of the WT mice than on the
backs of the B-KO mice (Figure 4E).
DNCB Treatment Promotes Differentiation of Th Cells
into Th2 Cells
In the present study, we also probed the changes of cytokine
profiles as well as lymphocyte compositions in the lymph nodes to
determine whether there was a distinct immunological shift in the
Th cell functions following DNCB treatments. We found that
DNCB treatments promoted the differentiation of Th cells into
Th2 cells, which appeared to provide a mechanistic basis for the
predominant induction of DNCB-specific Abs as an important
pathogenic change underlying the development of CHS. Some of
the findings are summarized below.
Changes in cytokine profiles. After in vitro culture for 60 h,
the primary lymphocytes collected from lymph nodes (LNs) of
mice that received triple DNCB sensitizations, proliferated four
times faster than cells from control mice that received vehicle
during sensitizations and challenge. Lymphocytes in LNs from
mice with double sensitizations proliferated approximately three
times as fast as cells from the control animals (Figure 5A).
Several cytokines, including IL-2, IL-4, IL-10, IL-12 (p70) and
IFN-c, were detected in the culture medium of LN lymphocytes at
different time points (22 and 41 h). Multiple DNCB sensitizations
proportionally decreased the IL-12, which is secreted by
macrophages to induce Th1 cell development. Multiple DNCB
treatments also weakened the production of Th1 cytokines such as
IL-2 and IFN-c, while it increased the production of Th2 cytokines
such as IL-4 and IL-10 (Figure 5B).
Figure 5. Skewing of Th cells in the Th2 direction following DNCB treatment. A and B. Double DNCB sensitizations before challenge were
applied on D0 and D12 as described in Figure 1A whereas triple sensitizations were applied on D0, D7 and D13 as in Figure 2A. Both groups
received challenge on D17 and terminated a day later. A. Proliferation of lymphocytes as measured by using the [
3H]thymidine incorporation assay.
Lymphocytes were harvested from collected LNs and cultured in vitro under the stimulation of Con A at 5 mg/mL for 60 h. [
3H]Thymidine was
introduced for the final 14 h and the radioactivity (cpm) was measured using a Beta counter. * P,0.01 compared to the control group. Each value is
the mean6S.D. (N=4). B. Cytokine production by cultured lymphocytes. The supernatant from cultured lymphocytes was collected at 22 and 41 h,
and assayed using ELISA for cytokine concentrations. The cytokine production levels were normalized according to the relative cell density (based on
the radioactivity values from the cell proliferation assay). Each value is the mean6S.D. (N=3). C. The population of various cell types (TCRb
+,
CD3
+CD4
+, CD3
+CD8
+, B220
+, IgG
+, F4/80
+, and TCRcd
+) in the inguinal and postauricular lymph nodes of control and DNCB-treated mice. In this
experiment, the DNCB treatment regimen was the same as depicted in Figure 1A.*P,0.01 compared to the control group. Each value is the
mean6S.D. (N=6).
doi:10.1371/journal.pone.0007703.g005
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LNs (the predominantly local draining LNs) and inguinal LNs
(the systemic non-draining LNs), treatment of animals with
DNCB consistently decreased the populations of TCRab
+ and
CD3
+CD4
+ T cells (mostly Th cells), but increased the populations
of B220
+ and IgG
+ cells (mostly B cells) as well as the population of
F4/80
+ macrophages (Figure 5 and Figure S5). In comparison,
it had no appreciable effect on TCRcd
+ cells. DNCB also did not
differentially affect the percentages of different sub-populations of
lymphocytes (such as TCRab
+, CD3
+CD4
+ T cells, B220
+ and
IgG
+ B cells) in the local draining postauricular LNs versus the
systemic non-draining inguinal LNs.
Discussion
At present, the prevailing explanation is that the DNCB-induced
CHS is a condition predominantly mediated by cellular immune
responses [4–7]. In partial support of this hypothesis, earlier studies
reported that the severity of CHS was significantly lessened in mice
lacking either CD4
+ or CD8
+ T cells, and these data suggested that
the involvement of T cells in the development of CHS [7]. A recent
study demonstrated that galectin-1 could induce significant cell
death of Th1 and Tc1 cells but did not exert an appreciable
inhibition of CHS [14], thus suggesting that CHS is largely not
mediated by Th cells. In the presentstudy, we have gathered several
lines of experimental evidence (discussed below) which definitively
show that the formation of DNCB-specific Abs plays an important
role in the development of DNCB-induced CHS.
Firstly, we observed that before visible signs of DNCB-induced
inflammatory reactions in the back skin (the site of DNCB
application) could be observed, serum DNCB-specific Abs were
usually below the detection limit. However, once large quantities
of DNCB-specific Abs became detectable in sera, inflammatory
reactions at the back skin also started to appear. The titers of
DNCB-specific Abs were higher in animals sensitized multiple
times with DNCB compared to animals receiving a single DNCB
sensitization, and likewise, the severity of dermatitis at the site of
DNCB application was always higher in animals with multiple
DNCB sensitizations as opposed to single sensitization. Similar
observations were also made with ear swelling following DNCB
challenge. The concurrence of CHS and DNCB-specific Abs was
not only observed in the BALB/c mice, a strain that is usually
considered to be Th2-skewing [15,16], but it was also observed in
the C57BL/6 mouse strain, which tends to be Th1-shewing [15].
In addition, we observed that treatment of animals with DEX
strongly mitigated DNCB-induced CHS in both their back and ear
skins, and this inhibitory effect of DEX correlated closely with the
reduction of serum levels of DNCB-specific Abs (by ,50%) and
also IL-5-positive cells in the local hypersensitive sites.
Notably, we observed that in those animals that were sensitized
with DNCB only once and did not receive DNCB challenge later,
relatively mild skin hypersensitivity reactions were also developed
at the site of sensitization starting about eight days later. We
believe this phenomenon was not in contradiction with the
suggested causal role of DNCB-specific Abs in the development of
hypersensitivity reactions. The fact was that once DNCB was
painted on the mouse back skin, a fraction of the chemical would
remain on the back skin, as evidenced by the characteristic light
yellow color of this chemical remaining on their back skins well
after 8 days. When the DNCB-specific Abs were formed and
started to circulate in large quantities in the body (usually at 8 days
after the initial DNCB sensitization), the residual DNCB on the
mouse back skin would serve as a weak challenge, resulting in the
development of hypersensitivity reactions of the same type as seen
in those animals that were challenged with DNCB, although the
intensity, as expected, would be relatively milder. Notably, before
the antibodies became detectable, no hypersensitivity reactions
were seen in these animals. We believe the precise timing between
the appearance of hypersensitivity reactions and the appearance of
specific Abs, in fact, offers additional support for the importance of
specific Abs in the pathogenic process.
Secondly, we found that the adoptive transfer of DNCB-specific
antisera produced the strongest response to DNCB challenge in the
skins of recipient animals compared to the adoptive transfer of
lymphocytes or antisera + lymphocytes. Notably, in some of the
earlier studies [7,12], adoptive transfer of lymphocytes followed by
challengewiththesamehaptenwasusedtoinduceCHSinrecipient
animals. Under these experimental conditions, the ear swelling seen
in the recipient animals was always milder in severity compared to
animals sensitized directly with an allergen. However, the
observation made in the present study was distinctly different in
that the animals receiving the DNCB antisera had nearly the same
intensity of hypersensitivity skin reactions when challenged with
DNCB (note that theseanimals hadno priorDNCB exposure).This
distinction also points to the importance of the DNCB-specific Abs
in the pathogenesis of skin hypersensitivity reactions.
Here it should also be noted that while the blood levels of
DNCB-specific Abs in animals that were adoptively transferred
with DNCB antisera alone or antisera plus LN cells (both obtained
from DNCB-positive donors) were comparable, the ear swelling in
the latter was decreased when it was compared with the former.
While the mechanism of this suppressive effect exerted by LN cells
is not understood at present, it is speculated that some of the
components such as the suppressive regulatory T cells and/or
other inhibitory factors contained in the LN might exert an
inhibitory effect on the overall immune/inflammatory responses.
Thirdly, we found that the B cell-deficient mice (lacking mature B
cells and also the hapten-specific Abs) had markedly lower
hypersensitivity in their skin reactions and ear swelling compared
to the WT mice when the same DNCB treatments were given to
mice of both genotypes. This observation provides definitive
evidence for the critical role of B cells and hapten-specific Abs in
thepathogenicprocess.However,itshouldalsobenotedthatDNCB
could still induce, albeit to a much milder degree, inflammatory skin
reactions in the B-KO mice, which suggests that other cell types,
suchasnaturalkillercells[13],mayalso contribute to the pathogenic
process, in addition to B cells and their specific Abs.
In the present study, we have probed the changes in cytokine
profiles as well as lymphocyte compositions in the lymph nodes to
determine whether there is a distinct shift in the lymphocyte
functions following DNCB treatment. We found that DNCB
effectively induced the differentiation of T cells in the Th2
direction, which appears to provide a mechanistic basis for the
predominant induction of DNCB-specific Abs and their impor-
tance in the development of CHS. Our ex vivo experiments showed
that DNCB treatment in vivo increased Con A-stimulated release of
IL-4 and IL-10 but decreased Con A-stimulated release of IFN-c,
IL-2 and IL-12 (p70), and these effects were more pronounced
when multiple in vivo DNCB treatments were employed. In
addition, at the sites of hypersensitivity reaction (i.e., the painted
back skin and painted left ears), DNCB also increased the IL-5-
positive cells but decreased the IFNc-positive cells after multiple
applications of DNCB. Consistent with our observation of a Th2
shift following treatment with DNCB, earlier studies have
suggested that the IL-4-producing T cells may be involved in
the development of CHS [9,11,17–19]. It was also reported that
while IL-4 expression was increased in the lymph nodes, IL-5
expression was significantly elevated in the ear of animals topically
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Moreover, the severity of CHS was higher in IL-5 transgenic mice
that had a much higher level of IL-5 expression [21], whereas the
severity was markedly diminished in IL-4 deficient mice [18,22] or
in mice deficient in STAT6 (a mediator of IL-4’s biological
actions) [23]. Similarly, the results of the present study also showed
that the degree of ear swelling seen in the Th2-skewing BALB/c
mice treated with DNCB was significantly stronger than what was
seen in the Th1-skewing C57BL/6 mice receiving the same
DNCB treatment (Figure 2F and Figure 4B). Collectively, these
observations provide additional indirect evidence for the mecha-
nistic explanation proposed.
The results of our present study showed that administration of
DNCB induced the formation of DNCB-specific IgG1 to a
greater extent than other Ig subtypes. This observation is
consistent with our observation that DNCB treatments induced
Th2-skewing since Th2 cells are known to play an important role
in mediating the secretion of antigen-specific IgG1 from B cells
and IL-4 is known to induce isotype switching favoring IgG1
synthesis [24,25]. It is speculated that when the anti-DNCB IgG1
antibodies start to be formed in large quantities and circulate in
the body, they would conjugate with the antigen molecules
(applied during challenge) to form immune complex deposits,
which would subsequently activate the complement system and
thereby contribute to the development of hypersensitivity
reactions. This mechanistic element is usually characteristic of
many type III hypersensitivity reactions [26,27]. Although
DNCB-induced CHS has been mostly considered a type IV
hypersensitivity reaction, the findings of our present study
suggest that this condition may share some of the immunological
characteristics of both types III and IV reactions. More studies
are needed to further test this hypothesis.
The observations made in the present study in the mouse model
agreed well with some of the earlier observations made in patients
with contact dermatitis. It was reported earlier that there was an
increase in the expression of IL-4 and IL-5 mRNAs following
allergen challenge [19,28], together with an augmented Th2
response and a diminished Th1 response [29]. Similarly, the IL-4
producing cells in patients with dermatitis were increased in the
CD4
+ and CD8
+ T cell population among the peripheral blood
mononucleocytes [30]. Moreover, patients with contact dermatitis
had a higher percentage of peripheral blood lymphocytes
expressing Ig proteins when compared to normal subjects
[31,32], and repeated elicitations with antigen altered the balance
of cytokines released locally, with a shift toward Th2-dominated
responses [33]. All these observations are in accord with our data
showing a crucial role of Th2 cytokines and allergen-specific Abs
in the development of CHS. The human relevance of these
observations is expected to aid in the development of novel
approaches for treating human CHS conditions.
Lastly, it is of note that the skin CHS developed in rodents
following topical application of DNCB or other similar chemicals
has been used for decades by many researchers as a model to study
T cell-mediated hypersensitivity immune responses. At present, the
most commonly-adopted protocol includes the use of one DNCB
sensitization followed by one DNCB challenge 5 days later.
However, if the chemically-induced CHS is, in fact, mediated
predominantly by B cells and their specific Abs, the use of this
animal model may not serve the purposes as originally intended.
Based on the systematic comparison of various treatment methods
made in the present study, we also noticed that different methods of
DNCB administration could produce very different levels of
inflammatory ear swelling (Table S1). In general, factors like
gender, DNCB dosage, vehicles, and method of administration
appeared to be of little importance in the induction of ear swelling,
but the number of DNCB treatments and particularly the time
intervals between the treatments were found to be the most crucial
factors that affected the severity of ear swelling. If the intervals
between DNCB sensitizations were sufficiently long, usually 7 days
or longer, presumably for the animals to produce DNCB-specific
Abs,then highlyconsistent and marked ear swellingcould bereadily
observed. However, before DNCB-specific Abs became detectable,
the magnitude of ear swelling in DNCB-treated animals was almost
always under 50% regardless of the variations in other factors.
Conclusion
The results of our present study demonstrate that the presence of
DNCB-specific Abs plays an important role in the development of
CHS. The appearance of DNCB-induced skin dermatitis matches
in timing the appearance of DNCB-specific Abs in sera. Adoptive
transfer of sera containing DNCB-specific Abs from DNCB-treated
mice produces a much stronger hypersensitivity skin reaction than
the adoptive transfer of lymph node cells from the same donors.
Moreover, DNCB-induced CHS is markedly diminished in
transgenic B cell-deficient mice that cannot produce DNCB-specific
Abs. It was also observed that treatment of animals with DNCB
polarizes Th cells into Th2 differentiation by increasing the
production of Th2 cytokines (IL-4, IL-5 and IL-10)while decreasing
the production of Th1 cytokines (IFN-c and IL-2). Taken together,
these data demonstrate that the production of DNCB-specific Abs
by activated B cells plays an important role in the pathogenesis of
chemically-induced CHS. These observations may open up new
therapeutic targets for alleviating human CHS conditions.
Materials and Methods
Animal Experiments
Mice. All experimental protocols involving the use of live animals
were approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Kansas Medical Center (Kansas City,
KS). The 6- to 8-week-old male and female BALB/c mice and 7-week-
old female ICR mice were obtained from Harlan Laboratories
(Houston, TX). The B cell-deficient mice (B6.129S2-Igh-6
tm1Cgn/J)
and their background control C57BL/6J mice were obtained from the
Jackson Laboratory (ME, USA), and were raised in a sterile
environment. After arrival, they were allowed to acclimatize for
about a week before they were used in the experiment. The animals
were housed under controlled conditions of temperature (22uC) and
photoperiod (12 h light/12 h dark cycle), and the animals were
allowed free access to food and water throughout the experiment.
DNCB-induced contact dermatitis. To induce contact
dermatitis, the animals were sensitized multiple times with
painting 100 mL of 2% DNCB in 200-proof ethanol (ETOH)
onto the shaved back skin at different time intervals. Three to five
days after the last DNCB sensitization of the back skin, the animals
were challenged on their left ears with 20 mL of 2% DNCB in
ETOH once or twice. The control animals were painted with
ETOH alone. Twenty-four h later, the ear swelling was evaluated
by measuring the difference between the right and left ears in their
thickness (measured by using an engineer’s electronic micrometer)
and also their weight (based on measuring a small round piece cut-
out by using a sharp clamp).
The mice in the dexamethasone (DEX)-treated group received
i.m. injections of DEX at 10 mg/kg b.w. once every two days
beginning one day before the sensitization with DNCB and the
injections lasted until the end of the experiment.
Adoptive transfer of CHS. The donor BALB/c mice were
first immunized with DNCB or vehicle for three or four times, as
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ears, after which ear thickness and DNCB-specific IgG in serum
were measured. Positive donors (DNCB-treated) developed strong
hypersensitivity skin reaction and high titers of serum DNCB-
specific Abs, while the negative donors (vehicle-treated) did not
have appreciable hypersensitivity reaction or detectable levels of
DNCB-specific Abs. Twenty-four h after DNCB painting on the
left ears, mice from both groups were euthanized. Single-cell
suspensions were made from a pool of LNs from postauricle, axilla
and groin of the donor mice. Cell density was adjusted to
5610
8 cells/mL in PBS for injection. From the same animals,
fresh sera were also prepared. For the adoptive transfer, 100 mLo f
the lymphocyte suspension (5610
7 cells) or 300 mL of fresh serum
or combination of lymphocyte suspension and serum from positive
donors or negative donors was injected intravenously (i.v.) into
individual recipient mouse in different groups. After that, all
recipient animals were challenged on the left ears with 20 mLo f
2% DNCB twice with a 60-min interval. After 18 and 66 h, ear
swelling in the recipient mice was measured and serum DNCB-
specific Ab levels were determined by using ELISA.
Chemicals and Reagents
Dinitrochlorobenzene (DNCB, 99% purity) was purchased from
Acros Organics (NJ, USA). Tween-20, albumin from chicken egg
white (ovalbumin, 98% purity) and 1,2-phenylenediamine (OPD,
99.5% pure) were obtained from Sigma-Aldrich (MO,USA). Anti-
mouse CD3-PE, anti-mouse CD4-FITC, anti-mouse CD8a-PE-
Cy5, anti-mouse TCRb-PE, and anti-mouse TCRcd-PE were
purchased from BD Biosciences (CA, USA). Anti-mouse CD45R
(B220)-PE, anti-mouse F4/80-PE and purified anti-mouse IgA,
IgM were obtained from eBioscience (CA, USA). HRP-conjugated
anti-mouse IgA, IgG, IgG1, IgG2a, IgG2b, IgG3 and IgM were
obtained from Santa Cruz Biotechnology (CA, USA), and the
purified anti-mouse IgG, IgE as well as HRP-conjugated anti-
mouse IgE were obtained from Chemicon (CA, USA).
The DNP-ovalbumin conjugate was prepared by dissolving
600 mg ovalbumin in 60 mL sodium borate buffer (0.05 M,
pH 9.4). The solution was stirred at 4uC, and the DNCB powder
(0.01 mol) was gradually added into the solution. The conjugate
solution was stirred for 9 days at 4uC and then dialyzed against a
sodium borate buffer for 16 days at 4uC. It is of note that while 9
days of conjugation reaction followed by 16 days of dialysis
appeared to be very long, the outcome was much better than the
procedures of a 2-day conjugation followed by a 2-day dialysis.
The solution was centrifuged at 2000 rpm for 5 min. The
supernatants were sequentially dialyzed against distilled water for
6 days at 4uC. Conjugates were then lyophilized and stored at
280uC until use. This protocol used in this study was modified
according to an earlier study [34].
Flow Cytometric Analysis
Immediately after the LNs (postauricular and inguinal lymph
nodes), spleens and thymus were removed, they were grinded and
the cells were strained to obtain the single cell suspensions. For the
splenocytes, the red blood cells were lysed and washed before the
following steps. Cell number was determined by using a
hemocytometer. After incubation with the Ab conjugated with the
fluorochrome(s) (FITC or PE or PE-CY5 or three in combination)
followed by washing twice with PBS containing 2% FBS, the
samples were fixed with 2% paraformaldehyde in PBS overnight
and tested on a flow cytometer (Coulter EPICS XL-MCL 414102
from Beckman Coulter, Fullerton, CA). The data were analyzed
using the Expo 32 ADC and FlowJo7 software.
Histopathological and Immunohistochemical (IHC)
Analyses
Formalin-fixed, paraffin-embedded ear or back skin tissues were
sectioned at 5 mm in thickness, and the sections were stained with
hematoxylin and eosin (H&E). The pictures were taken with a light
microscope (magnification 1006).
IHC staining was performed according to the manufacturer’s
instructions with slight modifications. The ear and back skin tissues
were collected from BALB/c mice sensitized and then challenged
with DNCB or vehicle, and they were immediately frozen in dry-
ice and kept at 280uC. The frozen tissues were then embedded in
optimum cutting temperature compound (OTC) and cut into 6-
mm thick sections and then air-dried at room temperature for
30 min. During staining, the slides were fixed in 2% (v/v)
formaldehyde in PBS for 8 min at 4uC. After blocking the
endogenous peroxidase activity and endogenous biotin, the
sections were incubated overnight with a primary Ab (anti-mouse
IFN-c or anti-mouse IL-5) and then incubated with the
biotinylated secondary Ab in a humidified chamber (all Abs were
from R&D Systems, MN, USA). The slides were then incubated
with Vectastain Elite ABC-peroxidase (Vector Laboratories,
Burlingame, CA), then with 3, 39-diaminobenzidine (Vector
Laboratories, Burlingame, CA), and counterstained.
Measurement of DNCB-Specific Ab Levels in Sera
After the peripheral blood was collected, it was kept at room
temperatures for 1 h and then centrifuged at 3500 rpm (Eppendorf
5415r) at 4uC for 20 min, and the supernatants (sera) were stored
at 280uC in aliquots until use. The serum Abs were tested by
using ELISA, and all steps were carried out at room temperature.
For ELISA, the 96-well plates (obtained from NUNC) were first
coated with 0.1 mg/mL DNP-ovalbumin conjugate in 0.1 M
NaHCO3 overnight, and each well was then blocked with 0.25%
gelatin in PBS for 1 h followed by washing with 0.05% Tween-20
in PBS (washing buffer). Properly diluted serum samples were then
added into each well and incubated for 2–3 h. After 3 times of
washing, the HRP-conjugated detection Ab was added. After
incubation in the dark for 2 h and washing 3 times, the substrate
solution (containing 1 mg/mL OPD and 1.5 mL/mL 30%
hydrogen peroxide in 0.1 M citrate buffer, pH 5.0) was added
into each well. After incubation in the dark for another 30 min,
the plate was read on a Kinetic Microplate Reader (Molecule
Devices) at OD450 nm and OD570 nm. The final reading values
were calculated using OD450 nm–OD570 nm.
Assay of Primary Lymphocyte Proliferation and
Measurement of Cytokine Release
LN cells and splenocytes were isolated from BALB/c mice after
their left ears were challenged with DNCB or vehicle. Single-cell
suspensions were prepared as described above. LN cells were
seeded in 96-well plates at 5610
5 cells/well in 200 mL DMEM
containing 10% (v/v) fetal bovine serum, while splenocytes were
seeded in 96-well plate at 1610
6 cells/well in 200 mL medium.
The cells were stimulated with 5 mg/mL Con A. After 22 and
41 h, an aliquot of the cell culture supernatant was collected and
stored at 280uC for measurement of cytokine levels (described
below). To determine the rate of cell proliferation, 200 mL media
containing 2.5 mCi/mL [
3H]thymidine was added into each well.
After incubation for 14 h, cells were transferred onto the
membrane A by using a cell harvester and read on a Beta
scintillation counter (MicroBeta Trilux, PerkinElmer Life Sciences,
MA, USA).
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into the culture medium were measured by using the ELISA
according to the manufacturer’s instructions. Anti-mouse IL-4/
IFN-c (purified), recombinant mouse IL-4/IFN-c and anti-mouse
IL-4/IFN-c-biotin were purchased from eBioscience (CA, USA)
while the mouse IL-2, IL-10 and IL-12 (p70) cytokine ELISA kits
were obtained from BD Biosciences (CA, USA).
Statistical Analysis
All data are presented as mean6S.D. and were analyzed by
paired and unpaired two-tailed Student’s t tests. Difference between
the groups was considered statistically significant when P,0.05.
Supporting Information
Table S1 Comparison of ear swelling and the levels of DNCB-
specific serum Abs in mice under different DNCB treatment
conditions. In the experiments summarized below, the animal
gender, DNCB dose, treatment time, solvent, site of sensitization
and also other factors were changed to compare the degree of ear
swelling and the levels of DNCB-specific serum Abs.
Found at: doi:10.1371/journal.pone.0007703.s001 (0.07 MB
DOC)
Figure S1 The contact hypersensitivity reactions seen at 24 h
after painting 2% DNCB is not due to non-specific inflammatory
reactions
1. In one of the experiments shown above when 2%
DNCB was used as a challenge in the absence of prior DNCB
sensitization, we found that DNCB did not cause any significant
ear swelling. The detailed experimental condition and results for
this experiment are provided below. The mice as shown above in
the left bar (in both panels) were sensitized with 2% DNCB by
painting on their back skins on day 0 and challenged on their left
ears on day 5. The mice as shown in the middle bar were painted
with vehicle on their back skins on day 0 and challenged with
vehicle on their left ears on day 5. The mice as shown in the right
bar were only painted on their left ears with 2% DNCB. The ear
swelling was measured at 24 h after DNCB ear challenge. The ear
swelling indices were calculated according to the difference
between the DNCB-challenged left ear and the unchallenged
right ear using the following formula: index=the measured value
for the left ear/the measured value for the right ear - 1. * P,0.01
compared to animals sensitized and challenged with DNCB. NS:
no significance. Each value is the mean6S.D. (N=4 for each
group).
1FOOTNOTE: Consistent with the observation from the
above experiment, it is also of note that when the animals received
their first sensitization with 2% DNCB painted on their back skins,
no visible inflammatory changes were seen in the first few days
following the painting. This observation also showed that painting
2% DNCB alone did not cause significant non-specific inflamma-
tory reactions at the site of topical application (in this case, the
back skins) at early time points. Usually, relatively mild skin
inflammatory changes could be seen from 8 days after DNCB
painting (in the absence of DNCB challenge). Explanation for this
late inflammatory reaction is provided in the main text.
Found at: doi:10.1371/journal.pone.0007703.s002 (0.13 MB
DOC)
Figure S2 Effect of DEX treatment on the body weight and
organ weight indices in mice. In this experiment, the animals in
the DNCB or DNCB + DEX group were painted on D0 and D12
with DNCB on their shaved back skins (as sensitizations), and on
D17, the animals were challenged with painting DNCB on their
left ears. Painting of ETOH (which served as the solvent) was used
for the control group. All the animals in the DEX-treated group
also received i.m. injection of DEX once every other day starting
one day before the first DNCB sensitization. The body weight
change of the animals during the experiment is shown in panel A,
and the changes in the weight indices of spleen and thymus are
shown in panel B. * P,0.01 compared to the animals treated with
DNCB alone (N=6 for each group).
Found at: doi:10.1371/journal.pone.0007703.s003 (0.32 MB
DOC)
Figure S3 Correlation of the severity of CHS with serum levels
of DNCB-specific Abs. Serum levels of DNCB-specific Abs in mice
treated with DNCB, Control, or DNCB + DEX were collected on
D18 and assayed by using ELISA.
Found at: doi:10.1371/journal.pone.0007703.s004 (0.18 MB
DOC)
Figure S4 Effect of DNCB or DNCB + DEX treatment on the
total serum levels of various Ig subtypes. Blood samples were taken
on D18 following the first DNCB sensitization, and the total serum
levels of IgA, IgM, IgG, IgG1, IgG2a, IgG2b and IgG3 were
measured by using ELISA for all treatment groups (i.e., DNCB,
control, and DNCB + DEX) in BALB/c mice. The ELISA assays
were carried out in 96-well plates that were coated with respective
capture Abs diluted in 0.1 M NaHCO3, and other procedures
were the same as the measurement of the DNCB-specific Abs.
N=6 for each treatment group.
Found at: doi:10.1371/journal.pone.0007703.s005 (0.24 MB
DOC)
Figure S5 Changes in the cell populations (TCRb
+,
CD3
+CD4
+, B220
+ and IgG
+) in both inguinal and postauricular
lymph nodes following treatment with DNCB or vehicle. The
DNCB treatment schedule was the same as described in Figure 1A.
The data shown here were from one representative of four
separate experiments which all showed a similar trend.
Found at: doi:10.1371/journal.pone.0007703.s006 (0.52 MB
DOC)
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